CJC-1295 (No DAC)

CJC-1295 without DAC, also known as Modified GRF 1-29 or Mod GRF 1-29, is a synthetic 29-amino-acid peptide designed to stimulate the body’s natural production of growth hormone (GH). It is a modified version of growth hormone-releasing hormone (GHRH), which is normally produced by the hypothalamus and signals the pituitary gland to release GH. Four amino-acid substitutions improve the peptide’s resistance to enzymatic degradation. Unlike CJC-1295 with DAC, the no-DAC version does not contain an albumin-binding component, making it a shorter-acting growth hormone secretagogue.

Researchers are interested in Modified GRF 1-29 because growth hormone participates in fat metabolism, muscle and connective tissue maintenance, and the regulation of insulin-like growth factor 1 (IGF-1). The peptide is also frequently discussed alongside ipamorelin, which stimulates GH secretion through a different receptor pathway. Although related GHRH compounds and the DAC-containing version of CJC-1295 have demonstrated endocrine activity in human studies, direct controlled human evidence for the no-DAC form remains extremely limited. Benefits for fat loss, muscle growth, recovery, sleep, and healthy aging have not been clinically established for this specific compound, which remains investigational and is not FDA-approved.

CJC-1295 without DAC is designed to mimic growth hormone-releasing hormone (GHRH), a natural signal from the hypothalamus that instructs the pituitary gland to release growth hormone. The peptide contains structural modifications intended to improve stability while retaining GHRH receptor activity.

1. Activating the GHRH Receptor

• Natural GHRH binds to receptors located on somatotroph cells in the anterior pituitary gland.
• Modified GRF 1-29 is designed to activate these same receptors.
• Receptor activation stimulates intracellular cyclic AMP (cAMP) signaling, which promotes GH secretion.
• The resulting GH response would depend on pituitary function and normal endocrine feedback mechanisms.

2. Stimulating Growth Hormone Pulses

• Growth hormone is normally released in pulses rather than at a constant rate.
• Because Modified GRF 1-29 lacks the albumin-binding DAC modification, it is expected to produce shorter-lasting receptor stimulation.
• Its effects on human GH pulse amplitude, frequency, and duration have not been adequately characterized.
• Claims that it perfectly reproduces natural GH pulsatility or prevents receptor desensitization remain unproven.

3. Influencing the GH/IGF-1 Axis

• Growth hormone stimulates the production of insulin-like growth factor 1 (IGF-1), particularly in the liver.
• IGF-1 participates in tissue growth, cellular metabolism, and several anabolic signaling pathways.
• Whether Modified GRF 1-29 produces consistent or sustained IGF-1 increases in humans remains unknown.

4. Structural Resistance to Degradation

• Four amino-acid modifications distinguish Modified GRF 1-29 from native GHRH(1-29).
• D-alanine at position 2 improves resistance to DPP-4-mediated degradation.
• Glutamine at position 8, alanine at position 15, and leucine at position 27 were introduced to improve aspects of chemical or enzymatic stability.
• These changes increase the rationale for biological activity but do not establish a specific human half-life.

5. Difference Between No DAC and With DAC

• CJC-1295 with DAC contains an additional chemical component that permits covalent binding to circulating albumin.
• Albumin binding extends exposure, producing a measured half-life of approximately 5.8–8.1 days in the DAC-form human trial.
• Modified GRF 1-29 lacks this component and is expected to clear much more rapidly.
• Clinical results involving the DAC form cannot automatically be attributed to Modified GRF 1-29.

6. Potential Complementarity With Ipamorelin

• Ipamorelin activates the growth hormone secretagogue receptor (GHSR-1a), a different receptor from GHRH.
• Experimental research involving GHRH and ghrelin-related signaling suggests these pathways can interact to influence GH release.
• However, the specific combination of Modified GRF 1-29 and ipamorelin has not been validated in controlled human clinical trials.

The Key Difference: CJC-1295 without DAC is an experimental GHRH receptor agonist rather than injected growth hormone. Its proposed activity depends on the pituitary gland releasing endogenous GH. Increasing GH signaling does not automatically demonstrate improvements in body composition, tissue repair, or physical performance.

Researchers are interested in CJC-1295 without DAC because it offers a potential way to investigate growth hormone release through the body's natural GHRH signaling pathway without the prolonged albumin binding of CJC-1295 with DAC.

• Growth Hormone Signaling: Provides a model for studying how modified GHRH peptides activate pituitary GH release.
• GH/IGF-1 Regulation: May help researchers investigate endocrine feedback and growth-related signaling.
• Body Composition: Growth hormone influences fat metabolism and lean tissue regulation, creating interest in potential metabolic applications.
• Muscle Recovery: GH/IGF-1 pathways participate in normal tissue maintenance and protein metabolism.
• Connective Tissue: Researchers are interested in the relationship between growth hormone signaling and collagen-related processes.
• Sleep Physiology: Natural GH secretion is associated with sleep, especially early-night slow-wave sleep.
• Age-Related Endocrine Changes: Growth hormone secretion generally declines with age, motivating research into GHRH analogues.
• Combination Research: Ipamorelin and other ghrelin receptor agonists influence a separate pathway that may interact with GHRH signaling.

Research Limitation: These interests are based mainly on known GH physiology and research involving related compounds. No controlled human trial has demonstrated that Modified GRF 1-29 improves muscle mass, reduces visceral fat, accelerates injury recovery, or enhances sleep.

Modified GRF 1-29 has a plausible biological mechanism for stimulating growth hormone secretion, but its direct human clinical evidence is limited. Potential outcomes should be distinguished from findings involving long-acting CJC-1295 with DAC, other GHRH analogues, or prescribed growth hormone.

• Growth Hormone Release: Activation of GHRH receptors provides a mechanistic rationale for increasing endogenous GH secretion.
• IGF-1 Signaling: Increased GH can stimulate IGF-1 production, but the magnitude of this effect has not been established for Modified GRF 1-29 in humans.
• Fat Metabolism: GH influences lipolysis and metabolic substrate use; clinically meaningful fat loss from this specific peptide remains unproven.
• Lean Mass: Growth hormone pathways participate in tissue maintenance, but no human trial has demonstrated increased muscle mass or strength from the no-DAC compound.
• Connective Tissue: Potential effects on collagen metabolism provide a research rationale without proven injury-healing benefits.
• Exercise Recovery: Claims of reduced soreness or faster recovery are primarily anecdotal.
• Sleep Quality: Natural GH secretion is linked to sleep physiology, but improved sleep from this peptide has not been established.
• Healthy Aging: No evidence demonstrates that Modified GRF 1-29 slows biological aging or extends lifespan.

Important Related Human Finding: In a 2006 study of CJC-1295 with DAC, a single administration produced approximately two- to ten-fold increases in mean growth hormone concentrations and 1.5- to three-fold increases in IGF-1 concentrations. These increases persisted for several days because the molecule contained the long-acting DAC component.

Critical Evidence Distinction: The 2006 results are not direct clinical evidence for Modified GRF 1-29. The no-DAC peptide differs in molecular structure and expected pharmacokinetics.

Combination Research: Related GHRH and growth hormone secretagogue pathways can interact to influence GH secretion. However, claims that Modified GRF 1-29 plus ipamorelin reliably increases GH output two to three times more than either compound alone have not been confirmed in controlled human trials of that exact combination.

Human Evidence Limitation: There are no established randomized human efficacy trials demonstrating improvements in body composition, muscle strength, sleep, athletic performance, or longevity from CJC-1295 without DAC.

Research Perspective: The peptide's greatest scientific value currently lies in its proposed ability to stimulate GHRH receptor signaling. Meaningful therapeutic outcomes and long-term safety remain unproven.

CJC-1295 without DAC has not undergone sufficient human clinical testing to establish a safe or effective dose, administration frequency, or treatment duration. Most dosing information circulating online comes from research vendors, experimental communities, and extrapolations from related GHRH compounds.

Published Clinical and Community-Reported Dosing

Community-Reported Standalone Dosing Patterns

Administration Considerations:

• Subcutaneous Administration: The principal route described by research vendors and experimental communities, but human absorption and safety data for the no-DAC form remain insufficient.
• Frequency: Short-acting receptor activity is the rationale behind repeated-dose community schedules. The optimal frequency has not been established.
• Fasting: Community protocols often recommend waiting between food intake and administration. These specific fasting windows have not been validated in human clinical trials of Modified GRF 1-29.
• Bedtime Administration: Sometimes proposed to coincide with natural nighttime GH secretion, but improved clinical outcomes have not been demonstrated.
• Half-Life: A value near 30 minutes is frequently reported in commercial descriptions, but direct human pharmacokinetic confirmation for the no-DAC compound is lacking.
• Reconstitution: No FDA-approved injectable formulation, universal home-mixing procedure, or validated storage period exists for research-market preparations.
• Product Identity: CJC-1295 without DAC, with DAC, and acetate or other salt forms may be inconsistently labeled. A label alone does not establish molecular identity.
• Combination Products: Equal peptide mass in a blend does not establish equal biological activity or an appropriate human dose.

Important Distinction: Clinical amounts studied with CJC-1295 DAC cannot be transferred directly to Modified GRF 1-29. The compounds have substantially different expected pharmacokinetics.

Research Perspective: The community-reported amounts are presented for educational comparison, not as recommended doses. No human dose-ranging study has established an optimal amount, safe upper limit, or effective treatment schedule for CJC-1295 without DAC.

No clinically validated treatment cycle or washout period exists for CJC-1295 without DAC. Published human research involving CJC-1295 investigated the long-acting DAC formulation, while community protocols for Modified GRF 1-29 generally describe repeated administration over several weeks.

• Human Clinical Evidence: No established treatment duration exists for Modified GRF 1-29.
• Related DAC Research: Clinical investigations of CJC-1295 with DAC evaluated endocrine responses during studies lasting approximately four to seven weeks.
• Short Community Cycles: Four to eight weeks are sometimes described for experimental hormone-signaling protocols.
• Common Community Cycles: Eight to twelve weeks are frequently discussed.
• Extended Community Cycles: Some descriptions extend to sixteen weeks or longer, despite insufficient safety data.
• Intermittent Schedules: Five days on and two days off is a common community convention.
• Washout Periods: Six to twelve weeks are sometimes described, but no evidence establishes a necessary or beneficial interval.
• Repeated Courses: The endocrine and metabolic consequences of recurring exposure remain unknown.

Research Consideration: Natural GH secretion is regulated by multiple feedback mechanisms involving GHRH, somatostatin, ghrelin, GH, and IGF-1. There is no clinical evidence that informal cycling schedules prevent receptor desensitization or preserve normal pituitary function.

Important Limitation: No human study has demonstrated that a particular cycle improves fat loss, muscle recovery, or sleep. Community timelines describing predictable benefits after specific weeks are anecdotal rather than clinically validated.

CJC-1295 without DAC is frequently discussed alongside other experimental compounds that influence growth hormone secretion, body composition, and tissue repair. The most commonly described combination is Modified GRF 1-29 with ipamorelin, which activates a separate receptor involved in GH release.

Research Perspective: Simultaneous activation of the GHRH and ghrelin receptor pathways is biologically plausible as a means of influencing GH release. However, this does not demonstrate improved muscle growth, fat reduction, or safety for the commonly marketed CJC-1295 No DAC and ipamorelin blend.

Important Distinction: Combining multiple growth hormone secretagogues may increase endocrine exposure and make adverse effects more difficult to attribute to one compound. The absence of controlled human combination studies is a major evidence limitation.

The human safety profile of CJC-1295 without DAC remains inadequately characterized. Some adverse effects reported with CJC-1295 formulations or other growth hormone-related therapies provide reasons for caution, but they cannot be assigned a reliable incidence rate for Modified GRF 1-29.

Important FDA Safety Finding: The FDA has identified potential significant safety risks associated with CJC-1295, including increased heart rate, systemic vasodilatory reactions, immunogenicity, and uncertainty surrounding peptide characterization.

Related Endocrine Safety: Elevated growth hormone exposure can contribute to insulin resistance, edema, joint symptoms, and other complications. These risks are well recognized in growth hormone medicine but have not been quantified specifically for Modified GRF 1-29.

Human Evidence Limitation: The available clinical safety findings for long-acting CJC-1295 with DAC cannot establish the safety of the no-DAC version, particularly when combined with ipamorelin or other secretagogues.

Research Perspective: A shorter expected duration of receptor activity does not automatically mean lower risk. Modified GRF 1-29 remains an experimental endocrine-active peptide with an incomplete safety profile.

No FDA-approved contraindication profile exists for CJC-1295 without DAC because the compound has not undergone adequate human clinical development. Its proposed stimulation of growth hormone and IGF-1 signaling introduces several important medical considerations.

• Active Cancer: Growth hormone and IGF-1 participate in cellular growth and proliferation. Experimental GH stimulation warrants particular concern in individuals with active malignancy.
• Pregnancy and Breastfeeding: Reproductive, fetal-development, and lactation safety data are unavailable.
• Diabetes / Insulin Resistance: GH signaling can reduce insulin sensitivity and may complicate blood glucose management.
• Elevated IGF-1 / Acromegaly: Additional stimulation of the GH/IGF-1 axis may be inappropriate when these hormones are already elevated.
• Pituitary Disorders: Individuals with pituitary tumors or abnormal hypothalamic-pituitary function require specialist evaluation.
• Sleep Apnea: Excessive GH activity can be associated with worsening obstructive sleep apnea and changes in soft tissue.
• Heart Failure / Significant Edema: Potential fluid retention may be problematic in individuals with cardiovascular disease.
• Uncontrolled Hypertension: GH-related fluid changes and reported vasodilatory effects warrant caution.
• Kidney Disease: Fluid balance, metabolism, and elimination have not been adequately studied for this compound.
• Thyroid Disorders: GH activity can influence thyroid hormone metabolism, creating uncertainty about effects during experimental use.
• Diabetes Medications: Potential changes in glucose regulation may affect individuals receiving insulin or other glucose-lowering therapies.
• Growth Hormone / Secretagogue Combinations: Concurrent use with other GH-active substances may produce additive or unpredictable endocrine effects.
• Competitive Athletics: CJC-1295 and related GHRH analogues are prohibited under WADA Section S2.
• Unregulated Products: Inconsistent naming, peptide identity, purity, and formulation quality create additional risks.

Regulatory Caution: CJC-1295 without DAC is not FDA-approved for growth hormone deficiency, muscle growth, fat loss, sleep improvement, injury recovery, or anti-aging. No established human therapeutic dose or treatment protocol exists.

Important Distinction: Several precautions are based on the known physiology of growth hormone and IGF-1 rather than adverse outcomes demonstrated specifically with Modified GRF 1-29. The absence of clinical data makes the actual risk difficult to quantify.

Medical Consideration: Suspected growth hormone deficiency should be evaluated through established endocrinology testing. Random GH measurements or symptoms alone cannot reliably establish a need for growth hormone-related treatment.

CJC-1295 without DAC is designed to influence the growth hormone axis, making endocrine and metabolic measurements particularly relevant to future clinical research. However, no validated human monitoring schedule exists for this specific peptide.

Research Consideration: IGF-1 is generally a more stable indicator of longer-term GH-axis activity than a single random GH measurement because growth hormone is naturally released in pulses.

Body Composition Consideration: An increase in measured lean mass does not automatically mean new contractile muscle tissue has formed. Fluid retention can influence body composition measurements, making strength and function important complementary outcomes.

Important Limitation: Even normal IGF-1, glucose, and other laboratory values cannot establish that Modified GRF 1-29 is safe. No biomarker panel or testing interval has been validated specifically for this experimental compound.